tbuckley/cabot-search huggingface dataset:
OPTICAL COHERENCE TOMOGRAPHY GUIDED PERCUTANEOUS CORONARY INTERVENTION COMPARED WITH OTHER IMAGING GUIDANCE: A META-ANALYSIS
Authors: Hector M. Garcia, Kayode O. Kuku, Viana Azizi, Gebremedhin Melaku, Anh Bui, Jorge A. Torres-Borrero, Yael Meirovich, Aaphtaab Dheendsa, Solomon Beyene, Salahadin Abubakar, Alexandre H. Kajita, Michael J. Lipinski, Ron Waksman
Journal: Journal of the American College of Cardiology (2017)
Targeting the Insulin-Like Growth Factor-I Receptor (IGF-IR) in Multiple Myeloma Cells Using Selective IGF-IR Tyrosine Kinase Inhibitors.
Authors: Thomas Stromberg, Simon Ekman, Leonard Girnita, Johan Lennartsson, Ulf Hellman, Kristina Carlson, Anders Osterborg, Karin Vanderkerken, Magnus Axelson, Olle Larsson, Kenneth Nilsson, Helena Jernberg-Wiklund
Journal: Blood (2004)
CURRENT SMOKING, MICROVASCULAR PATHOLOGY AND ADVERSE OUTCOME AFTER ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: NEW PATHOPHYSIOLOGICAL INSIGHTS
Authors: Colin Berry, David Carrick, Jaclyn Carberry, Margaret McEntegart, Mark Petrie, Hany Eteiba, Martin Lindsay, Stuart Hood, Stuart Watkins, Andrew Davie, Ahmed Mahrous, Ify Mord, Nadeem Ahmed, Vannesa T.Y. May, Ian Ford, Naveed Sattar, Paul Welsh, Aleksandra Radjenovic, Keith Oldroyd, Caroline Haig
Journal: Journal of the American College of Cardiology (2017)
Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells
Authors: Le Qin, Yunxin Lai, Ruocong Zhao, Xinru Wei, Jianyu Weng, Peilong Lai, Baiheng Li, Simiao Lin, Suna Wang, Qiting Wu, Qiubin Liang, Yangqiu Li, Xuchao Zhang, Yilong Wu, Pentao Liu, Yao Yao, Duanqing Pei, Xin Du, Peng Li
Journal: Journal of Hematology & Oncology (2017)

Multiple iterations of chimeric antigen receptors (CARs) have been developed, mainly focusing on intracellular signaling modules. However, the effect of non-signaling extracellular modules on the expansion and therapeutic efficacy of CARs remains largely undefined. We generated two versions of CAR vectors, with or without a hinge domain, targeting CD19, mesothelin, PSCA, MUC1, and HER2, respectively. Then, we systematically compared the effect of the hinge domains on the growth kinetics, cytokine production, and cytotoxicity of CAR T cells in vitro and in vivo. During in vitro culture period, the percentages and absolute numbers of T cells expressing the CARs containing a hinge domain continuously increased, mainly through the promotion of CD4+ CAR T cell expansion, regardless of the single-chain variable fragment (scFv). In vitro migration assay showed that the hinges enhanced CAR T cells migratory capacity. The T cells expressing anti-CD19 CARs with or without a hinge had similar antitumor capacities in vivo, whereas the T cells expressing anti-mesothelin CARs containing a hinge domain showed enhanced antitumor activities. Hence, our results demonstrate that a hinge contributes to CAR T cell expansion and is capable of increasing the antitumor efficacy of some specific CAR T cells. Our results suggest potential novel strategies in CAR vector design.
INCREASED LEFT ATRIAL COMPLIANCE IS AN INDEPENDENT PREDICTOR OF IMPROVED FUNCTIONAL CAPACITY AFTER PERCUTANEOUS MITRAL VALVULOPLASTY
Authors: Bruno Ramos Nascimento, Guilherme Rafael S. Athayde, Lucas Junqueira, Juliana R. Soares, Thiago N.R. Reis, Gabriel P. Saad, William Esteves, Maria do Carmo Nunes
Journal: Journal of the American College of Cardiology (2017)
An Early Biomarker Algorithm Predicts Lethal Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation
Authors: Matthew J Hartwell, Umut Ozbek, Ernst Holler, Anne S. Renteria, Pavan R. Reddy, Mina Aziz, William J Hogan, Francis A Ayuk, Yvonne A Efebera, Elizabeth O. Hexner, Udomsak Bunworasate, Muna Qayed, Rainer Ordemann, Matthias Wolfl, Stephan Mielke, Attaphol Pawarode, Yi-Bin Chen, Steven M. Devine, Andrew C. Harris, Madan H. Jagasia, Carrie L Kitko, Mark R Litzow, Nicolaus Kroeger, Franco Locatelli, Ryotaro Nakamura, Ran Reshef, Wolf Roesler, Daniela Weber, Kitsada Wudhikarn, Gregory A Yanik, John E. Levine, James L.M. Ferrara
Journal: Blood (2016)
Error in Text and Table
Authors: Raluca Mihalache, Jos Verbeek
Journal: JAMA Internal Medicine (2016)

Michael K. Ong, MD, PhD; Patrick S. Romano, MD, MPH; Sarah Edgington, MA; Harriet U. Aronow, PhD; Andrew D. Auerbach, MD, MPH; Jeanne T. Black, PhD, MBA; Teresa De Marco, MD; Jose J. Escarce, MD, PhD; Lorraine S. Evangelista, RN, PhD; Barbara Hanna, RN, PhD; Theodore G. Ganiats, MD; Barry H. Greenberg, MD; Sheldon Greenfield, MD, MPH; Sherrie H. Kaplan, PhD, MPH; Asher Kimchi, MD; Honghu Liu, PhD; Dawn Lombardo, MD; Carol M. Mangione, MD, MSPH; Bahman Sadeghi, MD, MBS; Banafsheh Sadeghi, MD, PhD; Majid Sarrafzadeh, PhD; Kathleen Tong, MD; Gregg C. Fonarow, MD; for the Better Effectiveness After Transition–Heart Failure (BEAT-HF) Research Group
The efficacy and toxicity of 3-weekly TS-1 containing chemotherapy in patients with unresectable advanced gastric cancer.
Authors: Tae Yong Kim, Byeong IL Lee, Gyu IM Kim, Ju Young Kim, Jin Seok Ahn, Jiyoung Rhee, Sun Young Rha, Min-Hee Ryu, Hyun Woo Lee, Keun Wook Lee, Dae Young Zang, Byung Woog Kang, Jin Hyoung Kang, Hye Jin Kang, Eun-Kee Song, Jae Yong Cho, Tae-You Kim, Yeul Hong Kim
Journal: Journal of Clinical Oncology (2012)

e14580 Background: TS-1 has shown good efficacy against unresectable advanced gastric cancer (AGC). Conventionally TS-1 containing chemotherapy (CTx) is performed on 5-weekly or 6-weekly basis. We lack robust evidence for the efficacy and safety of 3-weekly TS-1 containing CTx. In Korea, 3-weekly TS-1 containing CTx can be used as off-label under permission of Health Insurance Review and Assessment service (HIRA). We and HIRA conducted this study to confirm the efficacy and tolerability of 3-weekly TS-1 containing CTx in unresectable AGC. Methods: We retrospectively analyzed patients with unresectable AGC who received 3-weekly TS-1 containing CTx between June 2007 and January 2011. In 3-weekly TS-1 monotherapy, TS-1 40-60mg depending on patient’s body surface area was administered orally twice a day for 14 days followed by a 1-week rest every 3 weeks. In 3-weekly TS-1/cisplatin combination CTx, TS-1 40mg/m 2 was given orally twice a day for 14 days followed by 1-week rest and cisplatin 60 mg/m 2 on day 1 was given by intravenous infusion every 3 weeks. Results: A total of 1372 patients (TS-1 monotherapy: 265 (19.3%), TS-1/cisplatin : 1107 (80.7%)) were enrolled from 31 institutions. Response rate of 3-weekly TS-1 monotherapy was 18.1%. Progression-free survival (PFS) and overall survival (OS) were 5.2 months (95% C.I., 4.5-5.9) and 14.3 months (95% C.I., 10.6-17.9), respectively. Response rate of 3-weekly TS-1/cisplatin was 29.4%. PFS and OS of 3-weekly TS-1/cisplatin were 6.8 months (95% C.I., 6.3-7.4) and 16.1 months (95% C.I., 14.4-17.9) respectively. Common toxicities of TS-1 monotherapy included nausea/vomiting (N/V) (13.6%), anemia (13.2%) and neutropenia (10.2%). However, the incidences of more grade 3/4 toxicities were less than 3.0%. All grades of neutropenia, N/V and anemia occurred in 35.4%, 21.1% and 13.3% of patients receiving 3-weekly TS-1/cisplatin. However, grade 3/4 toxicities including neutropenia, N/V and anemia occurred in only 17.8%, 3.0% and 2.9%. Conclusions: Three-weekly TS-1 monotherapy or TS-1/cisplatin CTx showed good efficacy and well tolerability. Our study suggests that 3-weekly scheduled regimens may be a good treatment option for unresectable AGC patients.
PATIENT BASED TERRITORIAL CORONARY FLOW ANALYSIS BY VORONOI ALGORITHM WITH 13N AMMONIA PET CTA FUSION
Authors: Kenji Fukushima, Yuka Matsuo, Mitsuru Momose, Michinobu Nagao, Nobuyuki Kihara, Stephan Nekolla, Akiko Sakai, Kayoko Sato, Nobuhisa Hagiwara, Shuji Sakai
Journal: Journal of the American College of Cardiology (2017)
First line treatment with weekly docetaxel, vinorelbine, and trastuzumab in HER2 overexpressing metastatic breast cancer (HER2+ MBC): A Minnie Pearl Cancer Research Network phase II trial
Authors: D. A. Yardley, F. A. Greco, L. L. Porter, H. A. Burris, C. Phelps, C. Webb, L. Schlabach, L. M. Fichtel, J. D. Hainsworth
Journal: Journal of Clinical Oncology (2004)

643 Background: The addition of trastuzumab to chemotherapy results in survival benefits in HER2+ MBC. Preclinical data suggests synergism between vinorelbine and docetaxel plus trastuzumab, with phase II trials of vinorelbine or docetaxel plus trastuzumab demonstrating significant activity with minimal toxicity. Recognizing the prerequisite to long term disease free survival is achievement of initial complete responses, we evaluated weekly trastuzumab administered with docetaxel and vinorelbine as 1st line therapy of HER2+ MBC. Methods: Primary end points were feasibility and toxicity of the regimen. Eligible patients (pts) had measurable disease, ECOG PS 0–2, 3+ HER2 overexpression by IHC or FISH, normal LVEF, and no prior chemotherapy or trastuzumab for MBC. Pts received vinorelbine (25mg/m2) and docetaxel (30mg/m2), days 1 & 8 q21 days. Trastuzumab was given at 4 mg/kg day 1 followed by 2 mg/kg/wk. Results: 35 pts have been treated with 29 evaluable for response. Median age was 58 years (range 41 - 79), 24 were postmenopausal, 8 FISH+ and 24 pts 3+ HER2+ by DAKO. Thirteen pts had prior therapy, 9 prior adjuvant therapy and 7 with prior taxanes. Majority of pts had > 2 organ sites of involvement with visceral lung metastases predominating. A median of 6 cycles (range 2 –22) was administered with 193 cycles evaluable for toxicity. Grade ¾ toxicities included: neutropenia (70%), febrile neutropenia (21%), fatigue (14%), hyperglycemia (10%), and myalgias (7%). At the time of analysis, the response rate was 75% with 10 (42%) partial responses and 8 (33%) complete responses. 4 had stable disease; 2 had disease progression. 3 deaths due to intercurrent illness were noted (myocardial infarction, renal failure, and GI bleed). 5 are unevaluable for response. PFS is 11.3 months. Conclusion: First line therapy with vinorelbine, docetaxel and trastuzumab in HER2+ MBC is feasible with manageable toxicity. Significant activity with a high complete response rate was noted, surpassing that reported for either agent alone combined with trastuzmab. Accrual continues; results to be updated. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech; GlaxoSmithKline Genentech; GlaxoSmithKline Genentech; GlaxoSmithKline; Aventis
Ablation of Dicer1 in Myeloid Progenitors Leads to Neutrophil Dysplasia and Depletion of Monocytes, Macrophages, and Myeloid Dendritic Cells
Authors: Mir Farshid Alemdehy, Nicole G.J.A. van Boxtel, Hans de Looper, Iris J. van den Berge, Mathijs A. Sanders, Tom Cupedo, Ivo P. Touw, Stefan J. Erkeland
Journal: Blood (2011)
Financial hardship associated with cancer in the United States.
Authors: K Robin Yabroff, Emily Dowling, Gery Guy, Matthew Banegas, Timothy S. McNeel, Amy J. Davidoff, Neetu Chawla, Danielle Blanch Hartigan, Xuesong Han, Erin E. Kent, Chunyu Li, Katherine S. Virgo, Juan Rodriguez, Janet de Moor, Zhiyuan Zheng, Ahmedin Jemal, Donatus U. Ekwueme
Journal: Journal of Clinical Oncology (2015)

6608 Background: Expenditures associated with cancer, its treatment, and lasting effects of treatment are increasing in the US. The purpose of this study is to estimate the prevalence of financial hardship associated with cancer and identify characteristics of cancer survivors associated with financial hardship. Methods: We identified 1,202 cancer survivors ages ≥ 18 years from the 2011 Medical Expenditure Panel Survey (MEPS) Experiences with Cancer survey. Material financial hardship was measured by ever 1) borrowing money or going into debt, 2) filing for bankruptcy, 3) being unable to cover their share of medical care costs, or 4) making other financial sacrifices due to cancer, its treatment or lasting effects of treatment. Psychological financial hardship was measured as worry about paying large medical bills. We examined factors associated with any material or psychological financial hardship using separate multivariable logistic regression models stratified by age group (18-64 and ≥ 65 years). Results: Cancer survivors ages 18-64 years were more likely to report any material financial hardship than those ages ≥ 65 years (28.4% vs 13.8%; p < 0.05). Worry about paying large medical bills was also more common among cancer survivors ages 18-64 years than those ages ≥ 65 years (31.9% vs 14.7%, p < 0.05). In adjusted analyses, cancer survivors ages 18-64 years who were younger, female, non-white, and treated more recently were significantly more likely to report any material financial hardship associated with cancer compared to those who were older, male, non-Hispanic white, and treated less recently. Those who were female, had lower family income, and treated more recently were more likely to report psychological financial hardship. Among cancer survivors ages ≥ 65 years, those who were younger and non-white were more likely to report any financial hardship (all p < 0.05). Conclusions: Cancer survivors commonly experience material and psychological financial hardship. The working age population is especially vulnerable. Efforts to characterize cancer survivors likely to experience financial hardship and improve patient-provider communication about affordability are crucial, especially with ongoing implementation of the Affordable Care Act.
A DIRECT COMPARISON OF ACCELERATED DISCHARGE STRATEGIES UTILISING A SINGLE HIGH SENSITIVITY TROPONIN T IN SUSPECTED ACUTE CORONARY SYNDROMES: PROSPECTIVE COHORT STUDY OF UNDETECTABLE TROPONIN T VERSUS LOW RISK TIMI, GRACE AND HEART SCORES (THE MACROS STUDY- MERSEY ACUTE CORONARY SYNDROME RULE-OUT STUDY)
Authors: Aleem Khand, Pei Chew, Freddy Frost, Michael Fisher, Grainger Ruth, Khaled Albouaini, Heidar Zadeh, James Dodd, Billal Patel, Mullen Liam
Journal: Journal of the American College of Cardiology (2017)
INSURANCE TYPE IS ASSOCIATED WITH LONGER HOSPITAL DURATION BUT SIMILAR MORTALITY AMONG CHILDREN UNDERGOING CONGENITAL HEART SURGERY
Authors: Kathleen Ryan, Claudia Algaze, Charlotte Sakarovitch, Thomas Do, Vamsi Yarlagadda, Susan Fernandes, Doff McElhinney, Stephen Roth, Catherine Krawczeski, Andrew Shin
Journal: Journal of the American College of Cardiology (2017)
LVAD-ASSOCIATED VON WILLEBRAND FACTOR DEGRADATION FRAGMENTS ALTER ANGIOGENESIS: A MECHANISTIC LINK BETWEEN LVAD SUPPORT, GASTROINTESTINAL ANGIODYSPLASIA, AND BLEEDING?
Authors: Carlo R. Bartoli, David Zhang, Jooeun Kang, David Restle, Pawel Kwiatkowski, Christian Bermudez, Michael Acker, Pavan Atluri, Patrick McConnell
Journal: Journal of the American College of Cardiology (2017)
浅大腿動脈(SFA)‐深部大腿動脈(DFA)分岐部病変に対するステント留置の12か月転帰
Authors: Yamawaki Masahiro, Muramatsu Toshiya, Tsukahara Reiko, Itou Yoshiaki, Sakai Tsuyoshi, Ishimori Hiroshi, Sasao Kenichiro, Nakano Masatsugu, Hirano Keisuke, Chatani Kenichi, Araki Motoharu, Takimura Hideyuki, Sakamoto Yasunari
Journal: Circulation (2009)
Murine TCL1 CLL Cells with B-Cell Receptors Specific for the Autoantigen Phosphatidylcholine Have a Selective Advantage During Adoptive Transfer
Authors: Shih-Shih Chen, Franak Batliwalla, Nichol Holodick, Xiao-Jie Yan, Thomas L. Rothstein, Nicholas Chiorazzi
Journal: Blood (2010)
Randomized phase II study of docetaxel with or without ramucirumab (IMC-1121B) or icrucumab (IMC-18F1) in patients with urothelial transitional cell carcinoma (TCC) following progression on first-line platinum-based therapy.
Authors: Daniel Peter Petrylak, Kim N. Chi, Nicholas J. Vogelzang, Guru Sonpavde, Mark D. Rutstein, Jonathan D. Schwartz, Floyd E. Fox, Weigang Wang, Leslie W Abad, Jan Cosaert, Dmitri O. Grebennik
Journal: Journal of Clinical Oncology (2012)

TPS4675^ Background: The vascular endothelial growth factor (VEGF) pathway may play an important role in the pathogenesis of bladder cancer. Two antibodies (ramucirumab or icrucumab) in combination with docetaxel are being tested in this clinical study. Ramucirumab is a fully human IgG1 monoclonal antibody (MAb) that specifically binds with high affinity to VEGF receptor-2 (VEGFR-2), thereby blocking the interaction of VEGF ligands. Ramucirumab inhibits VEGF-mediated proliferation of human endothelial cells and migration of human leukemia cells. Icrucumab is a fully human IgG1 MAb that specifically binds with high affinity to VEGFR-1 and blocks the binding of VEGF-A, VEGF-B, and placental growth factor (PlGF) to the receptor, thereby inhibiting subsequent signaling. Blockage of VEGFR-1 and VEGFR-2 by antibodies demonstrates antiangiogenic and antitumor activity and prevents dissemination and growth of lung metastases in several tumor xenograft models. Methods: This study includes patients (pts) with TCC with progressive disease after prior platinum-based therapy. Pts are randomized equally to 1 of 3 open-label treatments given on a 21-day cycle: docetaxel (75 mg/m 2 ) on Day 1 (Arm A); docetaxel on Day 1 and ramucirumab (10 mg/kg) on Day 1 (Arm B); or docetaxel on Day 1 and icrucumab (12 mg/kg) on Days 1 and 8 (Arm C). Randomization is stratified by the absence/presence of visceral metastases and receipt of prior antiangiogenic therapy. The primary endpoint is progression-free survival (PFS). Secondary outcome measures include response rate and duration of response, overall survival, and pharmacodynamic markers, including circulating levels of PlGF, VEGF-A, VEGF-B, soluble VEGFR-1, and soluble VEGFR-2. Exploratory analyses of VEGF, VEGFR-1, and VEGFR-2 genetic polymorphisms will be performed. As of 12 January 2012, approximately 20% of 138 planned pts were randomized in the US and Canada. The sample size will allow differentiation of an expected increase in median PFS from 3.0 months to 4.5 months with a one-sided alpha of 0.1 and a power of 71%. ClinicalTrials.gov identifier: NCT01282463.
The role of LHRH agonists in ovarian function preservation in premenopausal women undergoing chemotherapy for early stage breast cancer: A systematic review and meta-analysis.
Authors: Rodrigo Ramella Munhoz, Allan Andresson Lima Pereira, Andre Deeke Sasse, Paulo Marcelo Hoff, Tiffany A. Traina, Clifford A. Hudis, Ricardo Jose Marques
Journal: Journal of Clinical Oncology (2015)

1050 Background: The risks of chemotherapy-induced ovarian dysfunction and fertility impairment remain a clinical challenge in the management of premenopausal women diagnosed with early breast cancer (EBC). For this subgroup of patients (pts) undergoing treatment with curative intent, careful consideration of techniques to minimize these risks should be given. In this setting, the role of gonadotropin-releasing hormone agonists (GnRHa) for protection of ovarian function is not fully resolved. Methods: We searchedPubMed, SCOPUS and Cochrane Central Register of Controlled Trials databases, as well as ASCO Annual Meeting and San Antonio Breast Cancer Symposium abstracts. Prospective, randomized trials investigating the effect of GnRHa administered concurrently with chemotherapy (CT) for ovarian function preservation were selected for data extraction. Results: Six placebo-controlled studies were included in the analysis, totaling 827 randomized pts (673 evaluable pts). GnRHa used for ovarian suppression included either goserelin or triptorelin. Anthracycline and cyclophosphamide-based regimens were administered to over 90% of the pts in the neo- or adjuvant setting; a smaller proportion received taxanes. The use of GnRHa was associated with statistically significant improvement in the rate of recovery of regular menses after 6 months (OR = 2.53; 95% CI 1.23-5.22; p = 0, 01) and at least 12 months (OR 1.76; 95% CI 1.17-2.64; p = 0,007) following last CT cycle among evaluable pts. A higher number of pregnancies occurred among pts treated with GnRHa in comparison to the control arms, however, the total number of attempted pregnancies was not uniformly reported and this was not statistically significant (OR 1.79; 95% IC 0.97-3.31). Additional analyzes addressing mean time to recovery of menses and changes in hormonal levels were hampered by incomplete data. Conclusions: This meta-analysis provides evidence to support the use of GnRHa as a tool to prevent chemotherapy-induced amenorrhea in young women undergoing treatment for EBC. Additional outcomes related to ovarian function and fertility need to be further investigated.
STROKE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH CAROTID DISEASE UNDERGOING TAVR: INSIGHTS FROM THE STS/TVT REGISTRY
Authors: Ajar Kochar, Zhuokai Li, John Harrison, G. Chad Hughes, Vinod Thourani, Michael Mack, David Cohen, Eric Peterson, William Jones, Sreekanth Vemulapalli
Journal: Journal of the American College of Cardiology (2017)
Platelet-Derived Factor VIII (FVIII) Corrects the Murine Hemophilia A Phenotype Even in the Presence of FVIII Inhibitors.
Authors: Qizhen Shi, David A. Wilcox, Scot A. Fahs, Brian C. Cooley, Drashti Desai, Harmut Weiler, Patricia A. Morateck, Robert R. Montgomery
Journal: Blood (2005)
Weekly docetaxel and irinotecan for patients with advanced non-small cell lung cancer (NSCLC): Results of a multi-center, phase II study
Authors: S. Ramalingam, T. W. Dobbs, D. E. Coke, S. Wojtowicz-Praga, C. P. Belani
Journal: Journal of Clinical Oncology (2004)

7298 Background: The toxicity profiles of non-platinum regimens compare favorably to platinum-based combinations when used for the treatment of advanced NSCLC. Docetaxel and irinotecan, exhibit synergistic interaction in vitro and in vivo. Both agents also have documented single agent activity in NSCLC. We conducted a phase II study to evaluate the safety and efficacy of a weekly schedule of docetaxel in combination with irinotecan for patients with advanced NSCLC. Methods: Patients (N=45) with previously untreated stage IIIB (pleural or pericardial effusion)/IV NSCLC, ECOG PS < 2, normal hepatic, renal and bone marrow function were eligible. Docetaxel (35 mg/m2) and irinotecan (50 mg/m2) were administered on a weekly schedule for 4 consecutive weeks followed by a 2-week rest period (4 out of 6 weeks). Results: Baseline patient characteristics were: median age 60 years (range 38–76), males - 24, stage IIIB/IV - 11/34, adenocarcinoma - 20, squamous cell carcinoma - 12, large cell carcinoma - 4, undifferentiated carcinoma - 7. A total of 105 cycles of chemotherapy were administered. All patients were evaluable for toxicity and 36 patients were evaluable for efficacy. The results are summarized below: Conclusions: The combination of docetaxel and irinotecan administered on a weekly schedule is active for first-line treatment of patients with advanced NSCLC. The regimen was associated with the principal toxicity of grade 3/4 diarrhea, but the incidence of myelosuppression was low. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis Aventis Aventis Aventis